On 23 July 2024 the President of the Agency for Health Technology Assessment and Tariff System issued the following recommendation No. 73/2024 on the appropriateness of issuing approvals for the reimbursement of a medicinal product Agamree (vamorolone) in the indication Duchenne muscular dystrophy – treatment of pediatric patients